Schiff R - Search Results

1

Elacestrant and the Promise of Oral SERDs.

Sanchez KG, Nangia JR, Schiff R, Rimawi MF. Sanchez KG, et al. Among authors: schiff r. J Clin Oncol. 2022 Oct 1;40(28):3227-3229. doi: 10.1200/JCO.22.00841. Epub 2022 Jun 23. J Clin Oncol. 2022. PMID: 35737918 No abstract available.

2

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Mohsin SK, et al. Among authors: schiff r. J Clin Oncol. 2005 Apr 10;23(11):2460-8. doi: 10.1200/JCO.2005.00.661. Epub 2005 Feb 14. J Clin Oncol. 2005. PMID: 15710948 Clinical Trial.

3

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Gutierrez MC, et al. Among authors: schiff r. J Clin Oncol. 2005 Apr 10;23(11):2469-76. doi: 10.1200/JCO.2005.01.172. Epub 2005 Mar 7. J Clin Oncol. 2005. PMID: 15753463

4

Estrogen-receptor biology: continuing progress and therapeutic implications.

Osborne CK, Schiff R. Osborne CK, et al. Among authors: schiff r. J Clin Oncol. 2005 Mar 10;23(8):1616-22. doi: 10.1200/JCO.2005.10.036. J Clin Oncol. 2005. PMID: 15755967 Review. No abstract available.

5

Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Cui X, et al. Among authors: schiff r. J Clin Oncol. 2005 Oct 20;23(30):7721-35. doi: 10.1200/JCO.2005.09.004. J Clin Oncol. 2005. PMID: 16234531 Review.

6

Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.

Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Schiff R, et al. Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:10-20. doi: 10.1007/s00280-005-0108-2. Cancer Chemother Pharmacol. 2005. PMID: 16273359 Review.

7

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Massarweh S, et al. Among authors: schiff r. Cancer Res. 2006 Aug 15;66(16):8266-73. doi: 10.1158/0008-5472.CAN-05-4045. Cancer Res. 2006. PMID: 16912207

8

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R. Arpino G, et al. Among authors: schiff r. J Natl Cancer Inst. 2007 May 2;99(9):694-705. doi: 10.1093/jnci/djk151. J Natl Cancer Inst. 2007. PMID: 17470737

9

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Massarweh S, et al. Among authors: schiff r. Cancer Res. 2008 Feb 1;68(3):826-33. doi: 10.1158/0008-5472.CAN-07-2707. Cancer Res. 2008. PMID: 18245484

10

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.

Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM. Rimawi MF, et al. Among authors: schiff r. Cancer. 2010 Mar 1;116(5):1234-42. doi: 10.1002/cncr.24816. Cancer. 2010. PMID: 20082448 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

377 results

Search Page

Filters